Promising drug for hand and foot blisters falls short in early trial
NCT ID NCT05710185
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a daily pill called deucravacitinib in 3 adults with palmoplantar pustulosis (PPP), a painful skin condition causing blisters on palms and soles. The goal was to see if the drug could reduce disease severity by at least 50% over 24 weeks. However, the trial was terminated early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PALMOPLANTAR PUSTULOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug picankibart aims to treat stubborn hand and foot pustules
- Scientists seek skin samples to unlock secrets of common rashes
- New drug hope for painful hand and foot pustules
- AI boosts doctor accuracy for rare skin diseases in new study
- Spesolimab shows promise for Long-Term control of painful hand and foot pustules
- New drug shows promise for painful hand and foot psoriasis